We performed a correlation analysis of risk scores with selected ICIs, and the expression of BTLA, CD27, CTLA4, GPR65, HAVCR2, TIGIT and VSIG4 was upregulated in the high-risk group, suggesting that these new immune checkpoints may serve as potential candidate immunotherapy targets for PCa. The gene discussed is TIGIT; the disease is posterior cortical atrophy.